Posters

Deutetrabenazine (DTBZ) is used for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease. DTBZ dosing starts at 12 mg/d and is titrated up by 6 mg weekly, based on efficacy and tolerability, to a maximum of 48 mg/d. Due to individual variability in the pharmacokinetics of DTBZ, the dose needs to be titrated to an optimal dose for each individual while balancing efficacy and safety.

Deutetrabenazine is approved by the United States Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD). This interim analysis (cut off: August 2, 2024), explored patient-reported ease of use, effectiveness, and satisfaction with once-daily (QD) deutetrabenazine extended-release tablets.

Valbenazine is approved for the treatment of tardive dyskinesia (TD), a persistent and disabling movement disorder associated with prolonged antipsychotic exposure. Data from KINECT 3 were analyzed post hoc to evaluate changes in TD (based on Abnormal Involuntary Movement Scale [AIMS]) in participants with early treatment response (based on subjective global measures).

The long-term open-label extension study of rollover subjects (n=343) from the ARM-TD and AIM-TD trials evaluating the safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia (TD) presents an opportunity to objectively assess deutetrabenazine’s therapeutic effect.

Deutetrabenazine is approved to treat tardive dyskinesia (TD) in adults and is titrated weekly based on dyskinesia control and tolerability. This analysis compared the safety of deutetrabenazine during titration versus maintenance.